Tavokinogene telseplasmid clinical trials
Also written pIL-12.
- studies test it
- 9
- open now
- 0
- in phase 3
- 0
- first study started
- 2012
How each study uses tavokinogene telseplasmid is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2012 (3)
| Year | Studies |
|---|---|
| 2012 | 3 |
| 2015 | 2 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 9
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 3
OncoSec Medical Incorporated (6) · H. Lee Moffitt Cancer Center and Research Institute (1) · University of California, San Francisco (1) · Chase Heaton, MD (1)
Often tested with
Tested in the same studies.
Epacadostat (1) · SARS-CoV-2 Spike Protein Plasmid DNA Vaccine CORVax (1)
Studies
Open first, then newest update. How each study uses tavokinogene telseplasmid is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma PatientsCompletedPhase 2H. Lee Moffitt Cancer Center and Research InstituteNCT04526730Written as TavoHow we know
- Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBCActive, not recruitingPhase 2OncoSec Medical IncorporatedNCT03567720Written as tavokinogene telseplasmidHow we know
- IL-12 Gene and in Vivo Electroporation-Mediated Plasmid DNA Vaccine Therapy in Patients With Merkel Cell CancerCompletedPhase 2OncoSec Medical IncorporatedNCT01440816Written as Tavokinogene Telseplasmid (tavo)How we know
- Trial of pIL-12 Electroporation Malignant MelanomaCompletedPhase 2OncoSec Medical IncorporatedNCT01502293Written as Tavokinogene Telseplasmid (tavo)How we know
- Trial of pIL-12 Electroporation in Squamous Cell Carcinoma of the Head and Neck (IL12HNSCC)TerminatedPhase 2OncoSec Medical IncorporatedNCT02345330Written as Tavokinogene Telseplasmid (tavo)How we know
- Phase II Intratumoral IL12 Plasmid Electroporation in Cutaneous LymphomaTerminatedPhase 2OncoSec Medical IncorporatedNCT01579318Written as Tavokinogene Telseplasmid (tavo)How we know
- Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and EpacadostatTerminatedPhase 2Chase Heaton, MDNCT03823131Written as Tavokinogene telseplasmidHow we know
- Tavo and Pembrolizumab in Patients With Stage III/IV Melanoma Progressing on Either Pembrolizumab or Nivolumab TreatmentStatus unknownPhase 2OncoSec Medical IncorporatedNCT03132675Written as tavokinogene telseplasmidHow we know
- Trial of pIL-12/MK-3475 in Metastatic MelanomaCompletedPhase 2University of California, San FranciscoNCT02493361Written as pIL-12How we know
Codes
What other systems call tavokinogene telseplasmid · ClinicalTrials.gg INT017294
- UNII (FDA) MF4P7VQ2K8TAVOKINOGENE TELSEPLASMIDOne source FDA
- NCI Thesaurus C156363Tavokinogene TelseplasmidOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | MF4P7VQ2K8 | TAVOKINOGENE TELSEPLASMID | One source FDA |
| NCI Thesaurus | C156363 | Tavokinogene Telseplasmid | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.